XGN - Exagen Debt to Book Capitalization Ratio

Exagen Inc. (XGN) specializes in laboratory diagnostics, leveraging a team of leading scientists in autoimmune pathologies united by a common scientific goal. The development of the AVISE test system generates tangible financial results, with the current figure standing at 2.33. The linear price action on the chart below confirms the business's resilience to external shocks due to its local US operating model and minimal dependence on imports.

This indicator is calculated as the ratio of total borrowings to net asset value, allowing an investor to distinguish an undervalued asset from a company with a critical debt load. By analyzing the current liability structure relative to the book capitalization of Exagen Inc. (XGN), one can assess the extent to which the costs of developing diagnostic centers and implementing proprietary biomarkers in rheumatology are funded by equity rather than risky debt.